P553: A PHASE 2, OPEN-LABEL, MULTIARM, MULTICENTER STUDY TO EVALUATE MAGROLIMAB COMBINED WITH ANTILEUKEMIA THERAPIES FOR FIRST-LINE, RELAPSED/REFRACTORY, OR MAINTENANCE TREATMENT OF ACUTE MYELOID LEUKEMIA

• P. Vyas,
• N. G. Daver,
• M. P. Chao,
• G. Xing,
• C. Renard,
• G. Ramsingh,
• A. H. Wei,
• D. A. Sallman

Affiliations

P. Vyas

1 Weatherall Institute of Molecular Medicine, MRC Molecular Hematology Unit, University of Oxford, MRC Molecular Haematology Unit and Oxford Biomedical Research Centre, University of Oxford and Oxford University Hospitals, Oxford, United Kingdom

N. G. Daver

2 The University of Texas MD Anderson Cancer Center, Houston

M. P. Chao

3 Gilead Sciences, Inc., Foster City, United States of America

G. Xing

3 Gilead Sciences, Inc., Foster City, United States of America

C. Renard

3 Gilead Sciences, Inc., Foster City, United States of America

G. Ramsingh

3 Gilead Sciences, Inc., Foster City, United States of America

A. H. Wei

4 Department of Haematology, Alfred Hospital and Monash University, Melbourne, Australia

D. A. Sallman

5 Moffitt Cancer Center, Tampa, United States of America